INTRODUCTION
Tuberculosis (TB) is causing approximately 2 million deaths annually. This major health problem is aggravated further by the association of the disease with the HIV epidemic and with the emergence of multidrug drug-resistance (MDR). Chemotherapy can be effective, but poor patient compliance, due to the long (6-9 months) duration of the treatment leads to clinical relapse and to the emergence of MDR strains of Mycobacterium tuberculosis. Therefore, new treatment strategies are required, that could be employed for MDR tuberculosis, or as preventive treatment of AIDS patients at high risk of developing TB.
The efficacy of passive antibody treatment for various intracellular bacterial infections, including tuberculosis has been a subject of recent debate [1, 2] . Unlike the variable, and sometimes contradictory outcomes of early studies with polyclonal antisera, recent application of monoclonal antibodies (mAb) showed consistently protective activity against a number of intracellular pathogens, such as Cryptococcus neoformans [3] .
Listeria monocytogenes [4] and Ehrlichia chaffensis [5] . Notably, these studies demonstrated that mAbs acted intracellularly against L. monocytogenes or revealed an extracellular phase of the E. chaffensis infection. Intratracheal infection with antiarabinomannan IgG3 opsonised Mtb was reported to prolong the survival of mice, but enhanced the granulomatous infiltration of the lungs, while the bacterial load was not reduced [6] . In contrast, Hamasur et al [7] reported a substantial decrease in the lung bacterial load, in addition to prolonged long-term survival, in mice inoculated intravenously with a lipoarabinomannan (LAM) specific IgG1 mAb. Opsonization of M.
bovis with an IgG1 mAb against the MPB83 surface glycoprotein also prolonged the survival of mice and changed the morphology of lung granulomas [8] .
Recently, we reported that intranasal (i.n.) application of an IgA mAb directed against the α-crystallin (acr1) antigen of M. tuberculosis was protective against early tuberculous pulmonary infection of mice [9] .This protective effect of IgA mAb was shown to be both epitope and isotype specific, since another IgA mAb, directed against 38 kDa antigen, as well as an IgG1 against α-crystallin, were much less effective. Inoculation of the antibody both before and after the aerosol challenge was required for optimal reduction of lung colony forming units (CFU), but this effect was not significant beyond 9 days post infection. Aiming to prolong the protection, we hypothesised that IgA-opsonised bacilli could be killed more efficiently by IFNγ activated alveolar macrophages. This was based on our observation, that IgA and IFNγ synergistically inhibit the growth of J774 mouse macrophage cells lines and induce TNFα synthesis and apoptosis in mouse peritoneal exudate macrophages [10] . In this study, we investigated whether intranasal coadministration of IFNγ and the IgA anti-acr1 mAb could impart greater and longer lasting protection against M. tuberculosis pulmonary infection in vivo.
MATERIALS AND METHODS

MAbs used in this study
TBA61 IgA mAb against surface expressed α-crystallin homologue antigen (acr1, hsp16.3, hspX or16 kDa antigen) [11] was purified from hybridoma supernatants (CL- 
Passive protection and aerosol infection studies
The passive protection experiments were carried out as previously described [9] . Briefly, CFUs), at a flow rate of 55 l/min, for 5 minutes. Lungs and spleens were harvested at 9, 21 and 28 days following the challenge, and 1 ml homogenates in 10-fold serial dilutions were plated on Middlebrook 7H11 agar plates, and incubated for three weeks at 37°C to determine organ CFU. 
Histopathology of lungs: morphometric analysis
In vitro infection studies
MH-S cells (mouse alveolar macrophages, obtained from European Collection of Cell
Cultures, Porton Down), were grown in RPMI 1640 medium supplemented with 10 % foetal bovine serum (FBS). Cells were seeded in 24-well plates with or without IFNγ (10 ng/ml) at high density (10 6 cell/well), which eliminated the inhibitory effect of IgA and
IFNγ on the growth of cells at low density [10] . After 24 hours of incubation, macrophages were infected (10 bacteria per 1 cell for 2 h at 37 o C) with luciferase tagged H37Rv M. tuberculosis [12] ) which had been pre-treated for 1 h at 37 o C with 50 µg/ ml of TBA61 or MOPC315 control IgA. After washing and 2 h treatment with amikacin (200 µg/ml) to kill the extracellular bacteria, cultures were either lysed in 0.1 % Triton X-100, to determine bacterial uptake, or further incubated for 4 days, prior to CFU and chemiluminescence assays. The medium was replaced after 2 days with RPMI 1640 containing only 2 % FBS (to minimise cell death in confluent cultures).
Macrophages from peritoneal exudates of Balb/c mice in RPMI 1640 medium with 10 % FBS, were allowed to adhere in 24 well culture plates overnight (5 x 10 5 cells/well), prior to addition of IFNγ (10 ng/ml). Following 2 day incubation, the cells were infected for 2 h with either IgA-opsonised, or non-opsonised bacilli, as described for MH-S cells. The amikacin treated, infected cells were returned to culture for a further 4 days. Finally, cells
were washed with PBS, lysed in 0.1 % Triton X-100 and dilutions of the lysate were used for enumeration of the infection by luminescence and by the standard CFU assay.
Detection of nitric oxide (NO) and TNFα
Culture supernatants obtained 24 h following the infection of peritoneal macrophages, were filter-sterilised. NO was measured using the Griess reagent (Sigma, Poole, UK), and the concentration determined from a standard curve obtained with sodium nitrite solution standards. TNFα was determined using the Bioscience (Middlesex, UK) detection kit, according to the manufacturer's instructions.
Statistical analysis
The effects of antibody on the degree of infection was analysed by Student's t-test and by the ANOVA test with multiple comparisons of means using Fisher's method.
RESULTS
The effect of combined inoculation of TBA61-IgA and IFNγ
The results of CFU counts in the lungs of experimental and control groups of BALB/c mice, harvested at three different time intervals are presented in Figure 2 . 
Pulmonary granuloma formation
Since a significant decrease in the lung bacterial load at the latest time point (4 weeks) after H37Rv infection was observed only for IgA/IFNγ treated group, we examined the extent of granulomatous lesions in lung sections of these mice, and compared them with the untreated controls. Representative sections are shown in Figure 3 A and B. 
Effect of IgA and IFNγ on the infection of macrophages in vitro
Following infection of MH-S cells, no difference could be observed in the 2 h bacterial uptake between TBA61 or control IgA treated luciferase-H37Rv, by either luminescence or CFU method (Fig.4) . tuberculosis. This outcome could have involved the following possible mechanisms. The exclusion of infection by antibodies [7] has been discounted on the grounds that the 24 h harvest following aerosol challenge did not result in a reduction of lung CFUs [9] and that TBA61 on its own did not inhibit infection of peritoneal macrophages or MH-S cells The acr1 specificity of the used IgA mAb could be significant. The other studies reporting protection, utilised mAbs to the glycolipid constituent, arabinomannan [6] or LAM [1, 7] , and against the strongly glycosylated MPB83 lipoglycoprotein [8] or the heparin-binding hemagglutinin (HBHA) glycoprotein [13] . LAM is known to be involved in the attachment of tubercle bacilli to macrophages [14] , while HBHA can influence the interaction with epithelial cells and extrapulmonary, e.g. splenic dissemination of the infection [13] , and therefore, antibodies could interfere with any of these functions. The synergistic effect of the anti-acr IgA and IFNγ in our studies appears to be confined to the lungs, since we could see no evidence for either increased or diminished dissemination of the infection to the spleen. Although the precise role of the acr1 antigen in the pathogenesis of TB is not known, there is evidence that its expression is required for bacterial growth inside macrophages [15, 16] . In that case, targeting of the acr1 antigen with TBA61 could possibly interfere with intracellular fate of the bacilli.
One possibility for this to happen would be via interaction involving Gal-3. Gal-3, an intracellular β-galactoside-binding lectin, was shown to be an important membrane constituent of the mycobacterial phagosome [17] . As we have demonstrated previously that IgA can interact with intracellular Gal-3 [18] , it is plausible that IgA binding to Gal- TBA61-IgA, 50 µg i.n.
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